Korean J Gastroenterol.  2024 Dec;84(6):243-250. 10.4166/kjg.2024.108.

Characteristics of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in Korea

• Kim TW
• Kim JS

• KMID: 2563341
• DOI: http://doi.org/10.4166/kjg.2024.108

Abstract

The prevalence of gastric mucosa-associated lymphoid tissue (MALT) lymphoma in Korea has not been reported largely because, it is a relatively rare disease. Gastric MALT lymphoma is clinically important because of the high prevalence of Helicobacter pylori (H. pylori) in Korea. The endoscopic findings of gastric MALT lymphoma are diverse, and it is often challenging to differentiate from gastric adenocarcinoma. Adequate tissue acquisition and testing for H. pylori are required for diagnosis. Neck, chest, and abdominopelvic CT scans should be performed with detailed patient history taking and a physical examination for accurate disease staging. The treatment for gastric MALT lymphoma depends on the disease stage and include H. pylori eradication therapy, radiation therapy, and chemotherapy. This manuscript summarizes the etiology, clinical characteristics, diagnosis, and treatment of gastric MALT lymphoma in Korea.

Keyword

Gastric MALT lymphoma; Helicobacter pylori

Reference

1. Kim JM, Ko YH, Lee SS, et al. 2011; WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol. 45:254–260. DOI: 10.4132/KoreanJPathol.2011.45.3.254.

2. Khalil MO, Morton LM, Devesa SS, et al. 2014; Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 165:67–77. DOI: 10.1111/bjh.12730. PMID: 24417667. PMCID: PMC3967856.

3. International Non-Hodgkin's Lymphoma Prognostic Factors Project. 1993; A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. DOI: 10.1056/NEJM199309303291402. PMID: 8141877.

4. Bertoni F, Coiffier B, Salles G, et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park). 2011; 25:1134–1142. 1147

5. Nakamura S, Matsumoto T, Suekane H, et al. 2005; Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer. 104:532–540. DOI: 10.1002/cncr.21152. PMID: 15937928.

6. Wotherspoon AC, Doglioni C, Diss TC, et al. 1993; Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 342:575–577. DOI: 10.1016/0140-6736(93)91409-F. PMID: 8102719.

7. Coyle WJ. 2010; Clinical trial report: eradication of Helicobacter pylori and MALT Lymphoma: where do we stand? Curr Gastroenterol Rep. 12:229–230. DOI: 10.1007/s11894-010-0118-z. PMID: 20532704.

8. Choi YJ, Kim N, Paik JH, et al. 2013; Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter. 18:197–205. DOI: 10.1111/hel.12033. PMID: 23305046.

9. Kim JS, Chung SJ, Choi YS, et al. 2007; Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer. 96:1324–1328. DOI: 10.1038/sj.bjc.6603708. PMID: 17406363. PMCID: PMC2360178.

10. Ryu KD, Kim GH, Park SO, et al. 2014; Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience. Gut Liver. 8:408–414. DOI: 10.5009/gnl.2014.8.4.408. PMID: 25071906. PMCID: PMC4113048.

11. Min BH, Park JY, Kim ER, et al. 2014; Limited role of bone marrow aspiration and biopsy in the initial staging work-up of gastric mucosa-associated lymphoid tissue lymphoma in Korea. Gut Liver. 8:637–642. DOI: 10.5009/gnl13284. PMID: 25368752. PMCID: PMC4215450.

12. Gong EJ, Ahn JY, Jung HY, et al. 2016; Helicobacter pylori eradication therapy is effective as the initial treatment for patients with H. pylori-negative and disseminated gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 10:706–713. DOI: 10.5009/gnl15510. PMID: 27114423. PMCID: PMC5003192.

13. Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. 2016; Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to H. pylori infection status. Gastroenterol Res Pract. 2016:6794848. DOI: 10.1155/2016/6794848. PMID: 27034656. PMCID: PMC4789472.

14. Kim JS, Park JC, Lee JY, et al. 2021; Long-term clinical outcomes of gastric MALT lymphoma: A nationwide multicenter study in Korea. Front Oncol. 11:681689. DOI: 10.3389/fonc.2021.681689. PMID: 34722238. PMCID: PMC8551628.

15. Jung H, Shin DW, Cheung DY, et al. 2023; Clinical impact assessment and utilization prospects of the t(11:18) chromosomal translocation in gastric MALT lymphoma in Koreans: A single center retrospective analysis. Korean J Gastroenterol. 81:29–35. DOI: 10.4166/kjg.2022.129. PMID: 36695064.

16. Thomas-Marques L, Yaziji N, Bouché O, Diebold MD, Cadiot G, Thiéfin G. 2005; Helicobacter heilmannii-associated low-grade gastric MALT lymphoma: a new case of complete remission after eradication. Gastroenterol Clin Biol. 29:476–477. DOI: 10.1016/S0399-8320(05)80823-1. PMID: 15918221.

17. Keikha M, Karbalaei M. 2022; Clinical aspects of Helicobacter heilmannii-associated gastritis in patients with dyspepsia: A systematic review and meta-analysis. Microb Pathog. 166:105518. DOI: 10.1016/j.micpath.2022.105518. PMID: 35405277.

18. Takigawa H, Masaki S, Naito T, et al. 2019; Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma. Cancer Med. 8:4370–4379. DOI: 10.1002/cam4.2314. PMID: 31210418. PMCID: PMC6675707.

19. Rollinson S, Levene AP, Mensah FK, et al. 2003; Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood. 102:1007–1011. DOI: 10.1182/blood-2002-12-3803. PMID: 12676777.

20. Liao F, Hsu YC, Kuo SH, et al. 2014; Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma. Blood Cancer J. 4:eXX. DOI: 10.1038/bcj.2014.70. PMID: 25303370. PMCID: PMC4220648.

21. Lin WC, Tsai HF, Kuo SH, et al. 2010; Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 70:5740–5748. DOI: 10.1158/0008-5472.CAN-09-4690. PMID: 20587516.

22. Della Bella C, Soluri MF, Puccio S, et al. 2021; The Helicobacter pylori CagY protein drives gastric Th1 and Th17 inflammation and B cell proliferation in gastric MALT lymphoma. Int J Mol Sci. 22:9459. DOI: 10.3390/ijms22179459. PMID: 34502367. PMCID: PMC8431018.

23. Keikha M, Sahebkar A, Yamaoka Y, Karbalaei M. 2022; Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis. J Health Popul Nutr. 41:2. DOI: 10.1186/s41043-021-00280-9. PMID: 34980267. PMCID: PMC8722127.

24. Tanaka T, Matsuno Y, Torisu T, et al. 2021; Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore). 100:e27287. DOI: 10.1097/MD.0000000000027287. PMID: 34559138. PMCID: PMC8462607.

25. Bertoni F, Zucca E. 2006; Delving deeper into MALT lymphoma biology. J Clin Invest. 116:22–26. DOI: 10.1172/JCI27476. PMID: 16395399. PMCID: PMC1323273.

26. Kwee I, Rancoita PM, Rinaldi A, et al. 2011; Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica. 96:1064–1066. DOI: 10.3324/haematol.2011.040402. PMID: 21459788. PMCID: PMC3128228.

27. Morgan JA, Yin Y, Borowsky AD, et al. 1999; Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 59:6205–6213.

28. Omote R, Gion Y, Omote S, et al. 2020; Clinicopathologic analysis of gastric mucosa-associated lymphoid tissue lymphoma with or without c-Met expression. Med Mol Morphol. 53:149–155. DOI: 10.1007/s00795-019-00241-6. PMID: 31897734.

29. Hyeon J, Lee B, Shin SH, et al. 2018; Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod Pathol. 31:1418–1428. DOI: 10.1038/s41379-018-0064-0. PMID: 29765142.

30. Zinzani PL. 2012; The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2012:426–432. DOI: 10.1182/asheducation.V2012.1.426.3798535. PMID: 23233614.

31. Cui X, Zhou T, Jiang D, et al. 2017; Clinical manifestations and endoscopic presentations of gastric lymphoma: a multicenter seven year retrospective survey. Rev Esp Enferm Dig. 109:566–571. DOI: 10.17235/reed.2017.4882/2017. PMID: 28617031.

32. Park BS, Lee SH. 2019; Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma. Yeungnam Univ J Med. 36:85–91. DOI: 10.12701/yujm.2019.00136. PMID: 31620618. PMCID: PMC6784630.

33. Choi MK, Kim GH. 2011; Diagnosis and treatment of gastric MALT lymphoma. Korean J Gastroenterol. 57:272–280. DOI: 10.4166/kjg.2011.57.5.272. PMID: 21623135.

34. Kim GH, Choi BG, Lee JN, et al. 2010; 2 cases of gastric mucosa-associated lymphoid tissue lymphoma presenting as a submucosal tumor-like lesion. Korean J Gastroenterol. 56:103–108. DOI: 10.4166/kjg.2010.56.2.103. PMID: 20729622.

35. Park EY, Kim GH. 2020; Extranodal marginal zone lymphoma: an unusual cause of gastric subepithelial tumor. Korean J Intern Med. 35:1530–1531. DOI: 10.3904/kjim.2020.059. PMID: 32306714. PMCID: PMC7652666.

36. Kim NI, Kim DH, Kim HS, Park SY, Cho HA, Kim HG. 2021; Gastric mucosa-associated lymphoid tissue lymphoma: An important differential diagnosis for a rapidly growing gastric subepithelial tumor-A case report and literature review. Korean J Helicobacter Up Gastrointest Res. 21:86–92. DOI: 10.7704/kjhugr.2020.0054.

37. Choi J. 2022; Successful Endoscopic resection of gastric mucosa-associated lymphoid tissue lymphoma unresponsive to Helicobacter pylori eradication therapy. Clin Endosc. 55:136–140. DOI: 10.5946/ce.2020.232. PMID: 33190433. PMCID: PMC8831412.

38. Gu H, Cheung DY, Seo YJ, et al. 2023; Five-year progress of gastric MALT lymphoma presenting as gastric outlet obstruction. Korean J Gastroenterol. 81:265–269. DOI: 10.4166/kjg.2023.026. PMID: 37350522.

39. Choi HI, Lee BE, Kim KB, Kim GH, Lee MW, Joo DC. 2023; Gastric mucosa-associated lymphoid tissue lymphoma mimicking signet ring cell carcinoma. Korean J Helicobacter Up Gastrointest Res. 23:132–136. DOI: 10.7704/kjhugr.2023.0018.

40. Gu SX, Siddon AJ, Huntington SF, Jain D. 2023; Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis. Am J Clin Pathol. 160:612–619. DOI: 10.1093/ajcp/aqad088. PMID: 37556379. PMCID: PMC10691190.

41. Resina Sierra E, Miranda García P, Adrados M, Santander Vaquero C. 2021; Pedunculated mucosa-associated lymphoid tissue (MALT) lymphoma causing gastric outlet obstruction. Rev Esp Enferm Dig. 113:842–843. DOI: 10.17235/reed.2021.8204/2021. PMID: 34315221.

42. Iwamuro M, Tanaka T, Nishida K, et al. 2019; Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis. Ecancermedicalscience. 13:933. DOI: 10.3332/ecancer.2019.933. PMID: 31281430. PMCID: PMC6605631.

43. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. 2007; American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 102:1808–1825. DOI: 10.1111/j.1572-0241.2007.01393.x. PMID: 17608775.

44. Gong EJ, Choi KD. 2019; Diagnosis and treatment of gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 74:304–313. DOI: 10.4166/kjg.2019.74.6.304. PMID: 31870136.

45. Gong EJ, Ahn JY, Jung HY, et al. 2016; Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma. Scand J Gastroenterol. 51:942–948. DOI: 10.3109/00365521.2016.1151929. PMID: 27149022.

46. Park JY, Kim SG, Kim JS, Jung HC. 2016; Bone marrow involvement is rare in superficial gastric mucosa-associated lymphoid tissue lymphoma. Dig Liver Dis. 48:81–86. DOI: 10.1016/j.dld.2015.10.008. PMID: 26548745.

47. Choi SI, Kook MC, Hwang S, et al. 2018; Prevalence and implications of bone marrow involvement in patients with gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 12:278–287. DOI: 10.5009/gnl17217. PMID: 29409307. PMCID: PMC5945259.

48. Park SH, Lee JJ, Kim HO, et al. 2015; 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 56:3288–3294. DOI: 10.3109/10428194.2015.1030640. PMID: 25804932.

49. Hwang JW, Jee SR, Lee SH, Kim JH, Seol SY, Lee SM. 2016; Efficacy of positron emission tomography/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 67:183–188. DOI: 10.4166/kjg.2016.67.4.183. PMID: 27112244.

50. Isaacson PG, Du MQ. 2004; MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 4:644–653. DOI: 10.1038/nrc1409. PMID: 15286744.

51. Isaacson PG, Spencer J. 1987; Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology. 11:445–462. DOI: 10.1111/j.1365-2559.1987.tb02654.x. PMID: 3497084.

52. Park G, Kang CS. 2012; Pathophysiology of gastric MALT lymphoma. Korean J Med. 83:689–698. DOI: 10.3904/kjm.2012.83.6.689.

53. Ayada Y, Igawa T, Naoi Y, et al. 2022; Immunohistochemistry for IRTA1 and MNDA helps differentiate gastric MALT lymphoma from chronic gastritis/reactive lymphocyte hyperplasia. J Clin Exp Hematop. 62:195–201. DOI: 10.3960/jslrt.22021. PMID: 36436933. PMCID: PMC9898717.

54. Bautista-Quach MA, Ake CD, Chen M, Wang J. 2012; Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol. 3:209–225.

55. Boot H. 2010; Diagnosis and staging in gastrointestinal lymphoma. Best Pract Res Clin Gastroenterol. 24:3–12. DOI: 10.1016/j.bpg.2009.12.003. PMID: 20206103.

56. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. 2003; Paris staging system for primary gastrointestinal lymphomas. Gut. 52:912–913. DOI: 10.1136/gut.52.6.912. PMID: 12740354. PMCID: PMC1773680.

57. Lemos FFB, de Castro CT, Calmon MS, et al. 2023; Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis. World J Gastroenterol. 29:2202–2221. DOI: 10.3748/wjg.v29.i14.2202. PMID: 37122607. PMCID: PMC10130965.

58. Wündisch T, Thiede C, Morgner A, et al. 2005; Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 23:8018–8024. DOI: 10.1200/JCO.2005.02.3903. PMID: 16204012.

59. Zucca E, Arcaini L, Buske C, et al. 2020; Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31:17–29. DOI: 10.1016/j.annonc.2019.10.010. PMID: 31912792.

60. B-Cell Lymphomas (Version 3.2024). [Internet]. National Comprehensive Cancer Network;Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. cited 2024 Oct 15.

61. Jung K, Kim DH, Seo HI, Gong EJ, Bang CS. 2021; Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis. Helicobacter. 26:e12774. DOI: 10.1111/hel.12774. PMID: 33400830.

62. Malfertheiner P, Megraud F, O'Morain C, et al. 2007; Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 56:772–781. DOI: 10.1136/gut.2006.101634. PMID: 17170018. PMCID: PMC1954853.

63. Liu H, Ye H, Dogan A, et al. 2001; T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 98:1182–1187. DOI: 10.1182/blood.V98.4.1182. PMID: 11493468.

64. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. 2010; Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol. 16:2158–2162. DOI: 10.3748/wjg.v16.i17.2158. PMID: 20440857. PMCID: PMC2864842.

65. Tomita N, Kodaira T, Tachibana H, Nakamura T, Mizoguchi N, Takada A. 2009; Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol. 90:231–235. DOI: 10.1016/j.radonc.2008.12.004. PMID: 19135751.

66. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. 2008; Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 87:405–411. DOI: 10.1016/j.radonc.2008.02.012. PMID: 18343513.

67. Schmelz R, Miehlke S, Thiede C, et al. 2019; pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial. J Gastroenterol. 54:388–395. DOI: 10.1007/s00535-018-1517-4. PMID: 30327875.

68. Aleman BM, Haas RL, van der Maazen RW. 2010; Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 24:27–34. DOI: 10.1016/j.bpg.2009.12.002. PMID: 20206106.

69. Dincer N, Ugurluer G, Gungor G, Zoto Mustafayev T, Atalar B, Ozyar E. 2022; Magnetic resonance imaging-guided radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. Cureus. 14:e29035. DOI: 10.7759/cureus.29035.

70. Chung JH, Na K, Kim IH. 2018; Benefit of volumetric-modulated arc therapy over three-dimensional conformal radiotherapy for stage I-II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the stomach: a dosimetric comparison. Radiat Oncol J. 36:332–340. DOI: 10.3857/roj.2018.00402. PMID: 30630272. PMCID: PMC6361246.

71. Sato M, Uematsu M, Hama Y, et al. 2000; Low-dose induction radiotherapy for stomach conservation in patients with massive gastric lymphoma. Tumori. 86:286–288. DOI: 10.1177/030089160008600405. PMID: 11016705.

72. Ueda K, Terui Y, Yokoyama M, et al. 2013; Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. Leuk Lymphoma. 54:1928–1933. DOI: 10.3109/10428194.2012.754023. PMID: 23216271.

73. No JH, Lee IS. 2012; Endoscopic findings and follow-up of gastric MALT lymphoma. Korean J Med. 83:699–705. DOI: 10.3904/kjm.2012.83.6.699.

74. Urakami Y, Sano T, Begum S, Endo H, Kawamata H, Oki Y. 2000; Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. J Gastroenterol Hepatol. 15:1113–1119. DOI: 10.1046/j.1440-1746.2000.02317.x. PMID: 11106089.

75. Min GJ, Kang D, Lee HH, et al. 2023; Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience. Ann Hematol. 102:877–888. DOI: 10.1007/s00277-023-05130-8. PMID: 36840791. PMCID: PMC9998564.

76. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. 2003; Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 52:1656. DOI: 10.1136/gut.52.11.1656. PMID: 14570741. PMCID: PMC1773845.

77. Couto ME, Oliveira I, Domingues N, et al. 2022; Gastric MALT lymphoma: A 8-year experience. Indian J Hematol Blood Transfus. 38:492–498. DOI: 10.1007/s12288-021-01483-0. PMID: 35747568. PMCID: PMC9209548.